{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:38:36Z","timestamp":1793893116311,"version":"4.8.0"},"reference-count":46,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,22]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Posttransplant high-dose cyclophosphamide (PTCy) is effective in overcoming the negative impact of HLA disparity in the haploidentical setting. In light of these results, we investigated the efficacy of PTCy, in improving clinical outcomes of hematopoietic stem cell transplantation (HSCT) from a mismatched unrelated donor (MMUD) in patients with acute myeloid malignancies by reducing the incidence and severity of acute graft-versus-host disease (aGVHD). A prospective, single-arm, phase 2 study (PHYLOS) was conducted by the Gruppo Italiano Trapianto di Midollo Osseo. The ethical committees of the participating centers approved the study (EURODRACT 2017-003530-85). A total of 77 consecutive patients (acute myeloid leukemia: 64; myelodysplastic syndrome: 13) were enrolled at 26 Italian transplant centers (January 2020-November 2022). Median age of the patients was 53 (range, 19-65) years. The 100-day cumulative incidence of grades 2 to 4 aGVHD was 18.2% (95%\u00a0CI, 10.6-27.6) and of grades 3 to 4 was 6.5% (95%\u00a0CI, 3.1-15.1). Seventy-one patients (92%) had full-donor chimerism with complete neutrophil engraftment by day\u00a0+30. One-year cumulative incidence of chronic GVHD was 13.4% (95%\u00a0CI, 6.9-22.1). One-year cumulative incidence of nonrelapse mortality was 9.1% (95%\u00a0CI, 4.0-16.9), and the relapse rate was 23.8% (95%\u00a0CI, 14.9-33.9). One-year overall survival and graft relapse-free survival were 78.6% (95%\u00a0CI, 67.4-86.3) and 55.3% (95%\u00a0CI, 43.4-65.7), respectively. Our study in a homogeneous patient cohort suggests that PTCy leads to a low rate of aGVHD and improves clinical outcomes of HSCT from MMUD. This trial was registered at www.clinicaltrials.gov as #NCT03270748.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015173","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T17:05:26Z","timestamp":1739207126000},"page":"1966-1975","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Posttransplant cyclophosphamide as GVHD prophylaxis in patients receiving mismatched unrelated HCT: the PHYLOS trial"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5118-4167","authenticated-orcid":false,"given":"Anna Maria","family":"Raiola","sequence":"first","affiliation":[{"name":"1Department of Hematology and Cellular Therapy, Istituo di Ricovero E Cura A Carattere Scientifico, Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7299-6770","authenticated-orcid":false,"given":"Benedetto","family":"Bruno","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Azienda Ospedaliera Universitaria Citta' della Salute e della Scienza di Torino, and Department of Biotechnologies and Health Sciences, University of Torino, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4744-5109","authenticated-orcid":false,"given":"Antonio Maria","family":"Risitano","sequence":"additional","affiliation":[{"name":"3Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Mosna","sequence":"additional","affiliation":[{"name":"4Hematology and Bone Marrow Transplantation Unit, Hospital of Bolzano (SABES-Azienda Sanitaria dell'Alto Adige), Teaching Hospital of Paracelsus Medical University, Bolzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene Maria","family":"Cavattoni","sequence":"additional","affiliation":[{"name":"4Hematology and Bone Marrow Transplantation Unit, Hospital of Bolzano (SABES-Azienda Sanitaria dell'Alto Adige), Teaching Hospital of Paracelsus Medical University, Bolzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2991-3474","authenticated-orcid":false,"given":"Francesco","family":"Onida","sequence":"additional","affiliation":[{"name":"5Hematology and Bone Marrow Transplantation Unit, Azienda Socio Sanitaria Territoriale Fatebenefratelli-Sacco, University of Milan, Milan, Italy"},{"name":"6Centro Trapianti Midollo Osseo e Terapie Cellulari-Struttura Complessa Ematologia, Fondazione Istituo di Ricovero E Cura A Carattere Scientifico, Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Saporiti","sequence":"additional","affiliation":[{"name":"6Centro Trapianti Midollo Osseo e Terapie Cellulari-Struttura Complessa Ematologia, Fondazione Istituo di Ricovero E Cura A Carattere Scientifico, Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Patriarca","sequence":"additional","affiliation":[{"name":"7Division of Hematology, S. Maria della Misericordia Hospital, Dipartimento di Medicina, Universit\u00e0 di Udine, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Lisa","family":"Battista","sequence":"additional","affiliation":[{"name":"7Division of Hematology, S. Maria della Misericordia Hospital, Dipartimento di Medicina, Universit\u00e0 di Udine, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1712-2744","authenticated-orcid":false,"given":"Vincenzo","family":"Pavone","sequence":"additional","affiliation":[{"name":"8Unit\u00e0 Operativa Complessa Ematologia con Trapianto, Azienda Ospedale Car Panico Tricase (Lecce), Tricase, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mele","sequence":"additional","affiliation":[{"name":"8Unit\u00e0 Operativa Complessa Ematologia con Trapianto, Azienda Ospedale Car Panico Tricase (Lecce), Tricase, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1355-1587","authenticated-orcid":false,"given":"Patrizia","family":"Chiusolo","sequence":"additional","affiliation":[{"name":"9Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"},{"name":"10Dipartimento di Scienze di laboratorio ed Ematologiche, Fondazione Policlinico A. Gemelli Istituo di Ricovero E Cura A Carattere Scientifico, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sica","sequence":"additional","affiliation":[{"name":"9Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"},{"name":"10Dipartimento di Scienze di laboratorio ed Ematologiche, Fondazione Policlinico A. Gemelli Istituo di Ricovero E Cura A Carattere Scientifico, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Loteta","sequence":"additional","affiliation":[{"name":"11Stem Cell Transplantation and Cellular Therapies Unit, Grande Ospedale Metropolitano, \u201cBianchi-Melacrino-Morelli,\u201d Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"di Grazia","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Cellular Therapy, Istituo di Ricovero E Cura A Carattere Scientifico, Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4967-4204","authenticated-orcid":false,"given":"Angelo Michele","family":"Carella","sequence":"additional","affiliation":[{"name":"12Department of Hematology and Stem Cell Transplant Unit, Fondazione Istituo di Ricovero E Cura A Carattere Scientifico Casa Sollievo della Sofferenza, Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalila","family":"Salvatore","sequence":"additional","affiliation":[{"name":"12Department of Hematology and Stem Cell Transplant Unit, Fondazione Istituo di Ricovero E Cura A Carattere Scientifico Casa Sollievo della Sofferenza, Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Morello","sequence":"additional","affiliation":[{"name":"13Blood Diseases and Cell Therapies Unit, Bone Marrow Transplant Unit, \u201cAzienda Socio Sanitaria Territoriale-Spedali Civili\u201d Hospital of Brescia, Brescia, Italy"},{"name":"14Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2177-2064","authenticated-orcid":false,"given":"Alessandro","family":"Leoni","sequence":"additional","affiliation":[{"name":"13Blood Diseases and Cell Therapies Unit, Bone Marrow Transplant Unit, \u201cAzienda Socio Sanitaria Territoriale-Spedali Civili\u201d Hospital of Brescia, Brescia, Italy"},{"name":"14Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Giaccone","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Azienda Ospedaliera Universitaria Citta' della Salute e della Scienza di Torino, and Department of Biotechnologies and Health Sciences, University of Torino, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bernasconi","sequence":"additional","affiliation":[{"name":"15Hematopoietic Stem Cell Unit, Hematology Department, Fondazione Istituo di Ricovero E Cura A Carattere Scientifico Policlinico San Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Terruzzi","sequence":"additional","affiliation":[{"name":"16Haematology Unit, Istituo di Ricovero E Cura A Carattere Scientifico San Gerardo, Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4969-1434","authenticated-orcid":false,"given":"Nicola","family":"Mordini","sequence":"additional","affiliation":[{"name":"17Division of Hematology, Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Borghero","sequence":"additional","affiliation":[{"name":"18Hematology Department, \u201cSan Bortolo\u201d Hospital, Vicenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Zallio","sequence":"additional","affiliation":[{"name":"19Hematology Department, SS Antonio and Biagio and C. Arrigo Hospital, Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Luppi","sequence":"additional","affiliation":[{"name":"20Ematologia, Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto, Universit\u00e0 degli Studi di Modena e Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2806-8336","authenticated-orcid":false,"given":"Anna","family":"Grassi","sequence":"additional","affiliation":[{"name":"21Hematology-Bone Marrow Transplantation Unit Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Olivieri","sequence":"additional","affiliation":[{"name":"22Clinica di Ematologia, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3256-7152","authenticated-orcid":false,"given":"Eugenia","family":"Piras","sequence":"additional","affiliation":[{"name":"23Hematology Unit, Businco Hospital, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7164-401X","authenticated-orcid":false,"given":"Nicoletta","family":"Sacchi","sequence":"additional","affiliation":[{"name":"24Italian Bone Marrow Donor Registry, E.O. Galliera Hospitals, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7644-9574","authenticated-orcid":false,"given":"Giovannino","family":"Ciccone","sequence":"additional","affiliation":[{"name":"25Unit of Clinical Epidemiology, Azienda Ospedaliera Universitaria Citt\u00e0 della Salute e della Scienza di Torino e Centro Prevenzione Oncologica Piemonte, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3415-3617","authenticated-orcid":false,"given":"Anna","family":"Castiglione","sequence":"additional","affiliation":[{"name":"25Unit of Clinical Epidemiology, Azienda Ospedaliera Universitaria Citt\u00e0 della Salute e della Scienza di Torino e Centro Prevenzione Oncologica Piemonte, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Degrandi","sequence":"additional","affiliation":[{"name":"26Trial Office Gruppo Italiano per il Trapianto di Midollo Osseo, cellule staminali emopoietiche e terapia Cellulare, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6512-6080","authenticated-orcid":false,"given":"Emanuele","family":"Angelucci","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Cellular Therapy, Istituo di Ricovero E Cura A Carattere Scientifico, Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3987-419X","authenticated-orcid":false,"given":"Massimo","family":"Martino","sequence":"additional","affiliation":[{"name":"11Stem Cell Transplantation and Cellular Therapies Unit, Grande Ospedale Metropolitano, \u201cBianchi-Melacrino-Morelli,\u201d Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1544-9911","authenticated-orcid":false,"given":"Francesca","family":"Bonifazi","sequence":"additional","affiliation":[{"name":"27Istituo di Ricovero E Cura A Carattere Scientifico Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"issue":"13","key":"2025042209063623900_bib1","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2007-06-097386","article-title":"High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation","volume":"110","author":"Lee","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2025042209063623900_bib2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0198-8859(90)90071-V","article-title":"Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma","volume":"29","author":"Anasetti","year":"1990","journal-title":"Hum Immunol"},{"issue":"7","key":"2025042209063623900_bib3","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood-2004-03-0803","article-title":"Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome","volume":"104","author":"Flomenberg","year":"2004","journal-title":"Blood"},{"issue":"6","key":"2025042209063623900_bib4","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.bbmt.2010.09.012","article-title":"HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation","volume":"17","author":"Woolfrey","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2025042209063623900_bib5","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3109\/10428194.2014.944518","article-title":"Allogeneic hematopoietic stem cell transplant for hematological malignancies from mismatched 9\/10 human leukocyte antigen unrelated donors: comparison with transplants from 10\/10 unrelated donors and human leukocyte antigen identical siblings","volume":"56","author":"Michallet","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2025042209063623900_bib6","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41408-017-0012-0","article-title":"Mismatched unrelated donor allogeneic stem cell transplant for high risk haematological malignancy: a single centre experience","volume":"7","author":"Mediwake","year":"2017","journal-title":"Blood Cancer J"},{"issue":"3","key":"2025042209063623900_bib7","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s12185-013-1405-x","article-title":"Effect of HLA mismatch on acute graft-versus-host disease","volume":"98","author":"Kanda","year":"2013","journal-title":"Int J Hematol"},{"issue":"1","key":"2025042209063623900_bib8","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2011-06-364265","article-title":"Risk factors for acute GVHD and survival after hematopoietic cell transplantation","volume":"119","author":"Jagasia","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2025042209063623900_bib9","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bmt.1705315","article-title":"HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation","volume":"37","author":"Ho","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"17","key":"2025042209063623900_bib10","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1182\/blood-2011-09-381699","article-title":"Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia","volume":"119","author":"Saber","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2025042209063623900_bib11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the US registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2025042209063623900_bib12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.bbmt.2018.08.026","article-title":"HLA-mismatched donors in patients with myelodysplastic syndrome: an EBMT registry analysis","volume":"25","author":"Robin","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2025042209063623900_bib13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/bmt.2014.259","article-title":"Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor","volume":"50","author":"Bachanova","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2025042209063623900_bib14","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.bbmt.2015.05.028","article-title":"HLA mismatch is associated with worse outcomes after unrelated donor reduced-intensity conditioning hematopoietic cell transplantation: an analysis from the Center for International Blood and Marrow Transplant Research","volume":"21","author":"Verneris","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2025042209063623900_bib15","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1200\/JCO.2003.03.129","article-title":"Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin","volume":"21","author":"Finke","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"2025042209063623900_bib16","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1182\/blood-2010-01-265413","article-title":"HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning","volume":"115","author":"Mead","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2025042209063623900_bib17","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1053\/j.seminoncol.2012.09.005","article-title":"Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation","volume":"39","author":"Luznik","year":"2012","journal-title":"Semin Oncol"},{"issue":"1","key":"2025042209063623900_bib18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbmt.2012.08.014","article-title":"Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning","volume":"19","author":"Raiola","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2025042209063623900_bib19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/nrclinonc.2015.128","article-title":"Modern approaches to HLA-haploidentical blood or marrow transplantation","volume":"13","author":"Kanakry","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"2025042209063623900_bib20","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bbmt.2009.11.011","article-title":"Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome","volume":"16","author":"Kasamon","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2025042209063623900_bib21","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"19","key":"2025042209063623900_bib22","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","article-title":"Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide","volume":"125","author":"McCurdy","year":"2015","journal-title":"Blood"},{"issue":"16","key":"2025042209063623900_bib23","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1182\/blood-2009-11-251595","article-title":"High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease","volume":"115","author":"Luznik","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2025042209063623900_bib24","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1182\/blood-2016-09-737825","article-title":"Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide","volume":"129","author":"Kanakry","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2025042209063623900_bib25","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1182\/blood-2015-10-672071","article-title":"Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation","volume":"127","author":"Mielcarek","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2025042209063623900_bib26","doi-asserted-by":"crossref","first-page":"776.e1","DOI":"10.1016\/j.jtct.2021.05.023","article-title":"Posttransplantation cyclophosphamide- and sirolimus-based graft-versus-host-disease prophylaxis in allogeneic stem cell transplant","volume":"27","author":"Greco","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"2025042209063623900_bib27","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1038\/s41409-021-01358-y","article-title":"Low-dose antithymocyte globulin plus low-dose posttransplant cyclophosphamide combined with cyclosporine and mycophenolate mofetil for prevention of graft-versus-host disease after HLA-matched unrelated donor peripheral blood stem cell transplantation","volume":"56","author":"Sun","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2025042209063623900_bib28","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.bbmt.2015.01.020","article-title":"Single-agent high-dose cyclophosphamide for graft-versus-host disease prophylaxis in human leukocyte antigen-matched reduced-intensity peripheral blood stem cell transplantation results in an unacceptably high rate of severe acute graft-versus-host disease","volume":"21","author":"Bradstock","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2025042209063623900_bib29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ejh.12541","article-title":"OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation","volume":"96","author":"Holtick","year":"2016","journal-title":"Eur J Haematol"},{"issue":"3","key":"2025042209063623900_bib30","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/bjh.13977","article-title":"Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation","volume":"173","author":"Mehta","year":"2016","journal-title":"Br J Haematol"},{"issue":"9","key":"2025042209063623900_bib31","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jtct.2021.06.018","article-title":"Post-transplant cyclophosphamide versus thymoglobulin in HLA-mismatched unrelated donor transplant for acute myelogenous leukemia and myelodysplastic syndrome","volume":"27","author":"Modi","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"2025042209063623900_bib32","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41409-019-0682-2","article-title":"Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation","volume":"55","author":"Nykolyszyn","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2025042209063623900_bib33","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41409-024-02225-2","article-title":"Graft-versus-host-disease prophylaxis with ATG or PTCY in patients with lymphoproliferative disorders undergoing reduced intensity conditioning regimen HCT from one antigen mismatched unrelated donor","volume":"59","author":"Paviglianiti","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2025042209063623900_bib34","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1182\/bloodadvances.2021004192","article-title":"Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant","volume":"5","author":"Al Malki","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2025042209063623900_bib35","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41409-023-02162-6","article-title":"Posttransplant cyclophosphamide in unrelated and related peripheral blood stem cell transplantation from HLA-matched and 1 allele mismatched donor","volume":"59","author":"Sugita","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2025042209063623900_bib36","doi-asserted-by":"crossref","first-page":"208.e1","DOI":"10.1016\/j.jtct.2022.12.017","article-title":"Three-year outcomes in recipients of mismatched unrelated bone marrow donor transplants using post-transplantation cyclophosphamide: follow-up from a National Marrow Donor Program-sponsored prospective clinical trial","volume":"29","author":"Shaw","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"2025042209063623900_bib37","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1182\/blood.2019000487","article-title":"Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation","volume":"134","author":"Battipaglia","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2025042209063623900_bib38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-024-01032-8","article-title":"PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation","volume":"14","author":"Penack","year":"2024","journal-title":"Blood Cancer J"},{"issue":"4","key":"2025042209063623900_bib39","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1182\/bloodadvances.2016002766","article-title":"Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide","volume":"1","author":"Kasamon","year":"2017","journal-title":"Blood Adv"},{"issue":"11","key":"2025042209063623900_bib40","doi-asserted-by":"crossref","first-page":"909.e1","DOI":"10.1016\/j.jtct.2021.08.013","article-title":"Nonmyeloablative, HLA-mismatched unrelated peripheral blood transplantation with high-dose post-transplantation cyclophosphamide","volume":"27","author":"Rappazzo","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"15","key":"2025042209063623900_bib41","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S1470-2045(15)00200-4","article-title":"Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial","volume":"16","author":"Rambaldi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"18","key":"2025042209063623900_bib42","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.20.03502","article-title":"National Marrow Donor Program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide","volume":"39","author":"Shaw","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"2025042209063623900_bib43","doi-asserted-by":"crossref","first-page":"1005042","DOI":"10.3389\/fonc.2022.1005042","article-title":"Outcomes with mismatched unrelated donor allogeneic hematopoietic stem cell transplantation in adults: a systematic review and meta-analysis","volume":"12","author":"Mushtaq","year":"2022","journal-title":"Front Oncol"},{"issue":"6","key":"2025042209063623900_bib44","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00277-019-03673-3","article-title":"Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study","volume":"98","author":"Soltermann","year":"2019","journal-title":"Ann Hematol"},{"issue":"17","key":"2025042209063623900_bib45","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1200\/JCO.20.01086","article-title":"McCrackenPhase II trial of costimulation blockade with abatacept for prevention of acute GVHD","volume":"39","author":"Watkins","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"2025042209063623900_bib46","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1038\/s41409-024-02400-5","article-title":"Young (&lt; 35 years) haploidentical versus old (\u2265 35 years) mismatched unrelated donors and vice versa for allogeneic stem cell transplantation with post-transplant cyclophosphamide in patients with acute myeloid leukemia in first remission: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"59","author":"Nagler","year":"2024","journal-title":"Bone Marrow Transplant"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/8\/1966\/2369313\/blooda_adv-2024-015173-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/8\/1966\/2369313\/blooda_adv-2024-015173-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T09:06:48Z","timestamp":1745312808000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/8\/1966\/535556\/Posttransplant-cyclophosphamide-as-GVHD"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,4,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015173","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]}}}